Condition: Stargardt Disease · Sponsor: Ray Therapeutics, Inc.
A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.
This description comes directly from the study's public registry record.
Executive Clinical Director · 858-617-8610 · clinicaltrials@raytherapeutics.com
Always discuss trial participation with your own doctor first.
| RayTx Clinical Site | Bakersfield, California, United States | Recruiting |
| UPMC Vision Institute | Pittsburgh, Pennsylvania, United States | Recruiting |
| RayTx Clinical Site | Bellaire, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07439887